accession_number stringlengths 20 20 | form_type stringclasses 5
values | filed_date stringdate 2026-02-23 00:00:00 2026-09-23 00:00:00 | period_of_report stringdate 2024-03-31 00:00:00 2026-08-31 00:00:00 | cik stringlengths 4 7 | ticker stringlengths 1 7 ⌀ | company_name stringlengths 2 54 | section stringclasses 5
values | item stringclasses 8
values | text stringlengths 80 410k | n_chars int32 80 410k | n_words int32 13 61.7k | filing_url stringlengths 94 97 | document_url stringlengths 76 98 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0001860173-26-000002 | 10-K/A | 2026-02-23 | 2025-07-31 | 1860173 | null | Privacy & Value Inc. | business | 1 | Business Overview
We were incorporated on April 21, 2021 under the laws of the state of Wyoming. We are involved in the development of computer monitoring software known as Privacy and Value. We have retained independent computer software and application developers to develop our product to the specifications that we o... | 16,839 | 2,629 | https://www.sec.gov/Archives/edgar/data/1860173/000186017326000002/0001860173-26-000002-index.htm | https://www.sec.gov/Archives/edgar/data/1860173/000186017326000002/pcvl-20250731_10ka.htm |
0001860173-26-000002 | 10-K/A | 2026-02-23 | 2025-07-31 | 1860173 | null | Privacy & Value Inc. | mdna | 7 | Introduction
We were incorporated on April 21, 2021 under the laws of the State of Wyoming.
Results of Operations for Fiscal 2025
During our fiscal year end of July 31, 2025, we incurred net loss of $51,445 due to general and administrative fees we incurred.
We have not attained profitable operations and are dependent ... | 6,955 | 1,079 | https://www.sec.gov/Archives/edgar/data/1860173/000186017326000002/0001860173-26-000002-index.htm | https://www.sec.gov/Archives/edgar/data/1860173/000186017326000002/pcvl-20250731_10ka.htm |
0001493152-26-040851 | 10-K | 2026-08-31 | 2026-05-31 | 73290 | BMRA | BIOMERICA INC | business | 1 | BUSINESS
OVERVIEW
THE
COMPANY
We are a global biomedical technology company that
develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Our diagnostic test kits are used to analyze
blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intoleran... | 39,766 | 5,751 | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/form10-k.htm |
0001493152-26-040851 | 10-K | 2026-08-31 | 2026-05-31 | 73290 | BMRA | BIOMERICA INC | risk_factors | 1A | Investing
in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together
with the other information in this Annual Report, including our consolidated financial statements and the related notes and “Management’s
Discussion and Analysis of Financial C... | 57,264 | 8,594 | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/form10-k.htm |
0001493152-26-040851 | 10-K | 2026-08-31 | 2026-05-31 | 73290 | BMRA | BIOMERICA INC | cybersecurity | 1C | We
have implemented and maintain an information security program designed to identify, assess, and manage material risks from cybersecurity
threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical
data including intellectual property, clinic... | 3,140 | 428 | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/form10-k.htm |
0001493152-26-040851 | 10-K | 2026-08-31 | 2026-05-31 | 73290 | BMRA | BIOMERICA INC | mdna | 7 | You
should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated
financial statements and the accompanying notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion and analysis
contains forward-looking statements ... | 41,713 | 6,055 | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/form10-k.htm |
0001493152-26-040851 | 10-K | 2026-08-31 | 2026-05-31 | 73290 | BMRA | BIOMERICA INC | market_risk | 7A | We
are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information
under this item. | 163 | 29 | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm | https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/form10-k.htm |
0001175680-26-000014 | 10-K | 2026-08-31 | 2026-05-31 | 1175680 | CYDY | CytoDyn Inc. | business | 1 | Corporate History/Business Overview
CytoDyn Inc. (together with its wholly owned subsidiary, the “Company”) was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage ... | 80,901 | 12,193 | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/0001175680-26-000014-index.htm | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm |
0001175680-26-000014 | 10-K | 2026-08-31 | 2026-05-31 | 1175680 | CYDY | CytoDyn Inc. | risk_factors | 1A | Our business is subject to numerous risks and uncertainties, including those highlighted in this section, which represent challenges we face in our efforts to successfully implement our strategy. You should carefully consider the risks described below in addition to other information set forth in this Form 10-K, includ... | 65,922 | 10,105 | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/0001175680-26-000014-index.htm | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm |
0001175680-26-000014 | 10-K | 2026-08-31 | 2026-05-31 | 1175680 | CYDY | CytoDyn Inc. | cybersecurity | 1C | We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to safeguard our information assets and operations from internal and external cyber threats, including protecting employee and patient information from una... | 2,398 | 327 | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/0001175680-26-000014-index.htm | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm |
0001175680-26-000014 | 10-K | 2026-08-31 | 2026-05-31 | 1175680 | CYDY | CytoDyn Inc. | mdna | 7 | The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the other sections of this Form 10-K, including our consolidated financial statements and related notes set forth in Part II, Item 8. This discussion and analysis contains forward-looking statem... | 32,935 | 5,125 | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/0001175680-26-000014-index.htm | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm |
0001175680-26-000014 | 10-K | 2026-08-31 | 2026-05-31 | 1175680 | CYDY | CytoDyn Inc. | market_risk | 7A | Interest Rate Risk
We are exposed to market risks in the ordinary course of business. Our primary exposure to market risk is sensitivity to changes in interest rates. We hold our cash in interest-bearing money market accounts; due to the short-term maturities of such financial instruments, a 100 basis point change in i... | 1,924 | 312 | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/0001175680-26-000014-index.htm | https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm |
0002076765-26-000009 | 10-K | 2026-08-31 | 2026-05-31 | 2076765 | ELVX | Elventix Technology Corp | business | 1 | General
Elventix Technology Corporation ("Elventix
", the "Company", "we", "us" or "our") was incorporated under the laws of the State of Wyoming,
U.S. on March 4, 2025 (Inception). The Company is an early-stage technology company focused on the development and commercialization of
"Smarterest," a mobile news aggregati... | 7,036 | 985 | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/0002076765-26-000009-index.htm | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/elventix_10k2026.htm |
0002076765-26-000009 | 10-K | 2026-08-31 | 2026-05-31 | 2076765 | ELVX | Elventix Technology Corp | cybersecurity | 1C | The Company is an early-stage company with no
employees and limited information technology infrastructure. The Company has not established a formal, documented cybersecurity risk management
program, and does not currently have a board committee or a management position specifically responsible for the assessment and ma... | 648 | 90 | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/0002076765-26-000009-index.htm | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/elventix_10k2026.htm |
0002076765-26-000009 | 10-K | 2026-08-31 | 2026-05-31 | 2076765 | ELVX | Elventix Technology Corp | mdna | 7 | and Results of Operations.
The following discussion should be read in conjunction
with our audited financial statements and the related notes appearing elsewhere in this annual report. The Company has a fiscal year ending
May 31. The comparative prior period presented is the period from March 4, 2025 (Inception) throug... | 4,873 | 779 | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/0002076765-26-000009-index.htm | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/elventix_10k2026.htm |
0002076765-26-000009 | 10-K | 2026-08-31 | 2026-05-31 | 2076765 | ELVX | Elventix Technology Corp | market_risk | 7A | Risk.
As a smaller reporting company, we are not required
to provide the information required by this Item. | 107 | 18 | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/0002076765-26-000009-index.htm | https://www.sec.gov/Archives/edgar/data/2076765/000207676526000009/elventix_10k2026.htm |
0001437749-26-029307 | 10-K | 2026-08-31 | 2026-05-31 | 1088413 | GLGI | GREYSTONE LOGISTICS, INC. | business | 1 | Organization
Greystone Logistics, Inc. (“Greystone” or the “Company”) was incorporated in Delaware on February 24, 1969, under the name Permaspray Manufacturing Corporation. It subsequently changed its name to Browning Enterprises Inc. in April 1982, to Cabec Energy Corp. in June 1993, to PalWeb Corporation in April 19... | 15,344 | 2,314 | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/0001437749-26-029307-index.htm | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/glgi20260531_10k.htm |
0001437749-26-029307 | 10-K | 2026-08-31 | 2026-05-31 | 1088413 | GLGI | GREYSTONE LOGISTICS, INC. | risk_factors | 1A | Our business could be affected by changes in the availability of raw materials.
Greystone uses a proprietary mix of raw materials to produce its plastic pallets. Such raw materials are generally readily available, and some may be obtained from a broad range of recycled plastic suppliers and unprocessed waste plastic. A... | 28,008 | 4,253 | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/0001437749-26-029307-index.htm | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/glgi20260531_10k.htm |
0001437749-26-029307 | 10-K | 2026-08-31 | 2026-05-31 | 1088413 | GLGI | GREYSTONE LOGISTICS, INC. | cybersecurity | 1C | Governance
While the Company does not employ a Chief Information Officer or consider cybersecurity threats to be a material risk to the business strategy, results of operations or financial position of the Company, the Board of Directors discusses risks and threats most applicable to the Company and inquires of managem... | 3,616 | 514 | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/0001437749-26-029307-index.htm | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/glgi20260531_10k.htm |
0001437749-26-029307 | 10-K | 2026-08-31 | 2026-05-31 | 1088413 | GLGI | GREYSTONE LOGISTICS, INC. | mdna | 7 | Cautionary Statement Regarding Forward-Looking Information
This Annual Report on Form 10-K includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements concern Greystone’s plans, ex... | 27,245 | 4,050 | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/0001437749-26-029307-index.htm | https://www.sec.gov/Archives/edgar/data/1088413/000143774926029307/glgi20260531_10k.htm |
0001493712-26-000010 | 10-K | 2026-08-31 | 2026-05-31 | 1493712 | STME | Stimcell Energetics Inc. | business | 1 | GENERAL
Stimcell Energetics Inc. was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed its wholly owned subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia.
Effective November 1, 2024, the Company completed... | 32,047 | 4,783 | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/0001493712-26-000010-index.htm | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/stme-20260531_10k.htm |
0001493712-26-000010 | 10-K | 2026-08-31 | 2026-05-31 | 1493712 | STME | Stimcell Energetics Inc. | risk_factors | 1A | There is a high degree of risk associated with buying the Company’s common stock. Prospective investors should carefully read this Annual Report on Form 10-K and consider the following risk factors when deciding whether to purchase the Company’s shares. These are speculative stocks and should be purchased by only those... | 22,256 | 3,394 | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/0001493712-26-000010-index.htm | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/stme-20260531_10k.htm |
0001493712-26-000010 | 10-K | 2026-08-31 | 2026-05-31 | 1493712 | STME | Stimcell Energetics Inc. | mdna | 7 | Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this Annual Report on Form 10-K constitute “forward-looking statements”. These statements, identified by words such as “plan,” “anticipate,” “believe,” “estimate,” “should,” “expect” and similar expressions include the Company’s e... | 12,853 | 2,032 | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/0001493712-26-000010-index.htm | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/stme-20260531_10k.htm |
0001493712-26-000010 | 10-K | 2026-08-31 | 2026-05-31 | 1493712 | STME | Stimcell Energetics Inc. | market_risk | 7A | We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f) of Regulation SK and are not required to provide the information required under this item. | 188 | 34 | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/0001493712-26-000010-index.htm | https://www.sec.gov/Archives/edgar/data/1493712/000149371226000010/stme-20260531_10k.htm |
0001375365-26-000022 | 10-K | 2026-08-31 | 2026-06-30 | 1375365 | SMCI | Super Micro Computer, Inc. | business | 1 | Our Company
We are a Silicon Valley-based provider of total information technology ("IT") solutions which address demanding workloads from the enterprise and cloud to the intelligent edge. We deliver rack-scale solutions optimized for various workloads, including artificial intelligence (“AI”) and high-performance comp... | 44,269 | 6,293 | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/0001375365-26-000022-index.htm | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/smci-20260630.htm |
0001375365-26-000022 | 10-K | 2026-08-31 | 2026-06-30 | 1375365 | SMCI | Super Micro Computer, Inc. | risk_factors | 1A | Our business involves significant risks, some of which are described below. Other events that we do not currently anticipate or that we currently deem immaterial also may affect our business, financial condition, results of operations, cash flows, other key metrics and the trading price of our common stock. You should ... | 124,998 | 18,918 | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/0001375365-26-000022-index.htm | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/smci-20260630.htm |
0001375365-26-000022 | 10-K | 2026-08-31 | 2026-06-30 | 1375365 | SMCI | Super Micro Computer, Inc. | cybersecurity | 1C | Risk Management and Strategy
We have in place certain infrastructure, systems, policies, and procedures that are designed to proactively and reactively address risks from cybersecurity threats. This includes processes for assessing, identifying, and managing material risks from cybersecurity threats. Our information se... | 4,929 | 656 | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/0001375365-26-000022-index.htm | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/smci-20260630.htm |
0001375365-26-000022 | 10-K | 2026-08-31 | 2026-06-30 | 1375365 | SMCI | Super Micro Computer, Inc. | mdna | 7 | The following discussion should be read in conjunction with the consolidated financial statements and related notes which appear elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in... | 53,952 | 8,401 | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/0001375365-26-000022-index.htm | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/smci-20260630.htm |
0001375365-26-000022 | 10-K | 2026-08-31 | 2026-06-30 | 1375365 | SMCI | Super Micro Computer, Inc. | market_risk | 7A | Investment and Interest Rate Risk
We are exposed to interest rate risk related to our fixed-rate investment portfolio and outstanding debt.
The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing the risk. Some of the securiti... | 2,577 | 405 | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/0001375365-26-000022-index.htm | https://www.sec.gov/Archives/edgar/data/1375365/000137536526000022/smci-20260630.htm |
0001472375-26-000211 | 10-KT | 2026-08-31 | 2025-12-31 | 1357878 | null | REGENEREX PHARMA, INC. | business | 1 | Business of
Issuer
Company Overview
The business of Regenerex Pharma,
Inc. (the “Company” or “Regenerex Pharma,”), is to develop and market Woundcare
Healing products. The Company has three technologies for different types of
wound conditions:
• | The first is for closing chronic wounds,
• | The second is for accelerat... | 15,571 | 2,318 | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/0001472375-26-000211-index.htm | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/ixform10kt.htm |
0001472375-26-000211 | 10-KT | 2026-08-31 | 2025-12-31 | 1357878 | null | REGENEREX PHARMA, INC. | risk_factors | 1A | The
Company will face competition from existing consumer
product companies.
We are an “emerging growth company” and we cannot be certain if the
reduced disclosure requirements applicable to emerging growth companies will
make our shares of common stock less attractive to investors.
We are an “emerging growth company,” ... | 16,161 | 2,502 | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/0001472375-26-000211-index.htm | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/ixform10kt.htm |
0001472375-26-000211 | 10-KT | 2026-08-31 | 2025-12-31 | 1357878 | null | REGENEREX PHARMA, INC. | cybersecurity | 1C | We recognize the importance of assessing, identifying, and managing
material risks associated with cybersecurity threats. These risks include, among other things: operational risks, intellectual property
theft, fraud, extortion, and violation of data privacy or security laws to
mitigate the threat to our business. The ... | 1,029 | 146 | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/0001472375-26-000211-index.htm | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/ixform10kt.htm |
0001472375-26-000211 | 10-KT | 2026-08-31 | 2025-12-31 | 1357878 | null | REGENEREX PHARMA, INC. | mdna | 7 | OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Plan of Operation
The
Company’s business is to develop
and market Woundcare
Healing products.
New Developments
Regenerex Pharma
Inc. has entered a pivotal phase of strategic expansion, with multiple
initiatives underway to strengthen our market position and operational
... | 10,230 | 1,580 | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/0001472375-26-000211-index.htm | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/ixform10kt.htm |
0001472375-26-000211 | 10-KT | 2026-08-31 | 2025-12-31 | 1357878 | null | REGENEREX PHARMA, INC. | market_risk | 7A | The Company’s market risk rises primarily from exposure to fluctuations
in interest rates and exchange rates. The
Company presently only transacts business in Canadian Dollars, U.S. Dollars,
and Malaysian Ringgits. Management
believes that the exchange rate risk surrounding future transactions of the
Company will not m... | 574 | 83 | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/0001472375-26-000211-index.htm | https://www.sec.gov/Archives/edgar/data/1357878/000147237526000211/ixform10kt.htm |
0001193125-26-376469 | 10-Q | 2026-08-31 | 2026-06-30 | 2119505 | null | Core University Living Real Estate Income Trust | risk_factors | II-1A | There have been no material changes to the risk factors previously disclosed in the Registration Statement, except as set forth below. The risk factors below supplement, and should be read together with, the risk factors described under “Item 1A. Risk Factors” in the Registration Statement.
Our portfolio is highly conc... | 2,323 | 336 | https://www.sec.gov/Archives/edgar/data/2119505/000119312526376469/0001193125-26-376469-index.htm | https://www.sec.gov/Archives/edgar/data/2119505/000119312526376469/d158029d10q.htm |
0001193125-26-376469 | 10-Q | 2026-08-31 | 2026-06-30 | 2119505 | null | Core University Living Real Estate Income Trust | mdna | I-2 | References herein to “Company,” “we,” “us,” or “our” refer to Core University Living Real Estate Income Trust and its subsidiaries unless the context specifically requires otherwise.
The following discussion should be read in conjunction with the unaudited consolidated financial statement and notes thereto appearing el... | 20,658 | 3,126 | https://www.sec.gov/Archives/edgar/data/2119505/000119312526376469/0001193125-26-376469-index.htm | https://www.sec.gov/Archives/edgar/data/2119505/000119312526376469/d158029d10q.htm |
0001193125-26-376469 | 10-Q | 2026-08-31 | 2026-06-30 | 2119505 | null | Core University Living Real Estate Income Trust | market_risk | I-3 | We will be exposed to interest rate risk with respect to any variable-rate indebtedness we have or will incur, whereas an increase in interest rates would directly result in higher interest expense. Interest rate risk is highly sensitive to many factors, including governmental, monetary and tax policies, domestic and i... | 869 | 131 | https://www.sec.gov/Archives/edgar/data/2119505/000119312526376469/0001193125-26-376469-index.htm | https://www.sec.gov/Archives/edgar/data/2119505/000119312526376469/d158029d10q.htm |
0001493152-26-040822 | 10-Q | 2026-08-31 | 2026-07-31 | 1263364 | COPR | Idaho Copper Corp | risk_factors | II-1A | We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required by this
item. Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
As described in Part I, Item 2, on April 17, 2026, and May 28, 2026, the Company sold convertible not... | 1,690 | 275 | https://www.sec.gov/Archives/edgar/data/1263364/000149315226040822/0001493152-26-040822-index.htm | https://www.sec.gov/Archives/edgar/data/1263364/000149315226040822/form10-q.htm |
0001493152-26-040822 | 10-Q | 2026-08-31 | 2026-07-31 | 1263364 | COPR | Idaho Copper Corp | mdna | I-2 | The
statements contained in the following MD&A and elsewhere throughout this Quarterly Report on Form 10-Q, including any documents incorporated
by reference, that are not historical facts, including statements about our beliefs and expectations, are “forward-looking statements”
within the meaning of the U.S. Private S... | 17,510 | 2,701 | https://www.sec.gov/Archives/edgar/data/1263364/000149315226040822/0001493152-26-040822-index.htm | https://www.sec.gov/Archives/edgar/data/1263364/000149315226040822/form10-q.htm |
0001493152-26-040822 | 10-Q | 2026-08-31 | 2026-07-31 | 1263364 | COPR | Idaho Copper Corp | market_risk | I-3 | We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this
item. Item
4. Controls and Procedures.
Evaluation
of Disclosure Controls and Procedures
The
Securities and Exchange Commission defines the term “disclosure controls and procedures” ... | 5,507 | 838 | https://www.sec.gov/Archives/edgar/data/1263364/000149315226040822/0001493152-26-040822-index.htm | https://www.sec.gov/Archives/edgar/data/1263364/000149315226040822/form10-q.htm |
0001683168-26-006817 | 10-Q | 2026-08-31 | 2026-03-31 | 1970129 | LGSP | LEGEND SPICES, INC. | mdna | I-2 | of Financial Condition and Results of Operations
FORWARD LOOKING STATEMENTS
This quarterly report contains forward-looking statements.
These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements
by terminology such as “may”, “should”, “expects... | 12,286 | 1,851 | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006817/0001683168-26-006817-index.htm | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006817/legend_i10q-033126.htm |
0001683168-26-006817 | 10-Q | 2026-08-31 | 2026-03-31 | 1970129 | LGSP | LEGEND SPICES, INC. | market_risk | I-3 | About Market Risk
As a “smaller reporting company”, we are
not required to provide the information required by this Item. | 121 | 20 | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006817/0001683168-26-006817-index.htm | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006817/legend_i10q-033126.htm |
0001683168-26-006819 | 10-Q | 2026-08-31 | 2026-06-30 | 1970129 | LGSP | LEGEND SPICES, INC. | mdna | I-2 | of Financial Condition and Results of Operations
FORWARD LOOKING STATEMENTS
This quarterly report contains forward-looking statements.
These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements
by terminology such as “may”, “should”, “expects... | 14,247 | 2,169 | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006819/0001683168-26-006819-index.htm | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006819/legend_i10q-063026.htm |
0001683168-26-006819 | 10-Q | 2026-08-31 | 2026-06-30 | 1970129 | LGSP | LEGEND SPICES, INC. | market_risk | I-3 | About Market Risk
As a “smaller reporting company”, we are
not required to provide the information required by this Item. | 121 | 20 | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006819/0001683168-26-006819-index.htm | https://www.sec.gov/Archives/edgar/data/1970129/000168316826006819/legend_i10q-063026.htm |
0002123169-26-000013 | 10-Q | 2026-08-31 | 2026-07-31 | 2123169 | null | Luvulis Corp | mdna | I-2 | of Financial Condition and Results of Operations.
DESCRIPTION OF BUSINESS
General
Luvulis Corporation (the “Company”
or “Luvulis”) is a development-stage technology company incorporated in the State of Wyoming on October 29, 2025. The Company
is focused on developing innovative and smart solutions for navigating global... | 16,297 | 2,331 | https://www.sec.gov/Archives/edgar/data/2123169/000212316926000013/0002123169-26-000013-index.htm | https://www.sec.gov/Archives/edgar/data/2123169/000212316926000013/luvulis10q_07312026.htm |
0002123169-26-000013 | 10-Q | 2026-08-31 | 2026-07-31 | 2123169 | null | Luvulis Corp | market_risk | I-3 | about Market Risk.
As a “smaller reporting company” as defined
by Item 10 of Regulation S-K, we are not required to provide information required by this Item. | 158 | 27 | https://www.sec.gov/Archives/edgar/data/2123169/000212316926000013/0002123169-26-000013-index.htm | https://www.sec.gov/Archives/edgar/data/2123169/000212316926000013/luvulis10q_07312026.htm |
0001185185-26-003760 | 10-Q | 2026-08-31 | 2026-03-31 | 1694617 | ROYL | Royale Energy, Inc. | mdna | I-2 | FORWARD-LOOKING
STATEMENTS
In addition to historical information contained herein, certain information
contained in this Quarterly Report on Form 10-Q, as well as other written and oral statements made or incorporated by reference from time
to time by the Company and its representatives in other reports, filings with t... | 11,021 | 1,750 | https://www.sec.gov/Archives/edgar/data/1694617/000118518526003760/0001185185-26-003760-index.htm | https://www.sec.gov/Archives/edgar/data/1694617/000118518526003760/royl10q033126.htm |
0001185185-26-003762 | 10-Q | 2026-08-31 | 2026-06-30 | 1694617 | ROYL | Royale Energy, Inc. | mdna | I-2 | and Results of Operations
FORWARD-LOOKING STATEMENTS
In addition to historical information contained herein,
certain information contained in this Quarterly Report on Form 10-Q, as well as other written and oral statements made or incorporated
by reference from time to time by the Company and its representatives in oth... | 12,763 | 2,043 | https://www.sec.gov/Archives/edgar/data/1694617/000118518526003762/0001185185-26-003762-index.htm | https://www.sec.gov/Archives/edgar/data/1694617/000118518526003762/royl10q063026.htm |
0001571123-26-000133 | 10-Q | 2026-08-31 | 2026-07-31 | 1571123 | SAIC | Science Applications International Corp | mdna | I-2 | The following discussion and analysis of our financial condition and results of operations and quantitative and qualitative disclosures about market risk should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes. It contains forward-looking statements (which may ... | 37,985 | 6,000 | https://www.sec.gov/Archives/edgar/data/1571123/000157112326000133/0001571123-26-000133-index.htm | https://www.sec.gov/Archives/edgar/data/1571123/000157112326000133/saic-20260731.htm |
0001571123-26-000133 | 10-Q | 2026-08-31 | 2026-07-31 | 1571123 | SAIC | Science Applications International Corp | market_risk | I-3 | There have been no material changes to our market risks from those discussed in our most recently filed Annual Report on Form 10-K. | 131 | 23 | https://www.sec.gov/Archives/edgar/data/1571123/000157112326000133/0001571123-26-000133-index.htm | https://www.sec.gov/Archives/edgar/data/1571123/000157112326000133/saic-20260731.htm |
0000779152-26-000067 | 10-K | 2026-08-28 | 2026-06-30 | 779152 | JKHY | JACK HENRY & ASSOCIATES INC | business | 1 | Jack Henry & Associates, Inc.® is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. For 50 years, we have provided technology solutions to help banks and credit unions innovate faster, strategically differentiate, and succes... | 48,965 | 6,811 | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/0000779152-26-000067-index.htm | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/jkhy-20260630.htm |
0000779152-26-000067 | 10-K | 2026-08-28 | 2026-06-30 | 779152 | JKHY | JACK HENRY & ASSOCIATES INC | risk_factors | 1A | The Company's business and the results of its operations are affected by numerous factors and uncertainties, some of which are beyond our control. The following is a description of some of the important risks and uncertainties that may cause our actual results of operations in future periods to differ materially from t... | 45,842 | 6,611 | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/0000779152-26-000067-index.htm | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/jkhy-20260630.htm |
0000779152-26-000067 | 10-K | 2026-08-28 | 2026-06-30 | 779152 | JKHY | JACK HENRY & ASSOCIATES INC | cybersecurity | 1C | Cyber Risk Management and Strategy
As a provider of products and services to financial institutions, Jack Henry integrates industry-standard frameworks, policies, and procedures to securely process and store sensitive information, prioritizing the protection of our associates, clients, and their private data in an ever... | 5,787 | 784 | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/0000779152-26-000067-index.htm | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/jkhy-20260630.htm |
0000779152-26-000067 | 10-K | 2026-08-28 | 2026-06-30 | 779152 | JKHY | JACK HENRY & ASSOCIATES INC | mdna | 7 | The following section provides management's view of the Company's financial condition and results of operations and should be read in conjunction with the audited consolidated financial statements, and related notes included elsewhere in this report. All dollar and share amounts, except per share amounts, are in thousa... | 40,517 | 6,118 | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/0000779152-26-000067-index.htm | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/jkhy-20260630.htm |
0000779152-26-000067 | 10-K | 2026-08-28 | 2026-06-30 | 779152 | JKHY | JACK HENRY & ASSOCIATES INC | market_risk | 7A | Dollar amounts in this item are in thousands.
Market risk refers to the risk that a change in the level of one or more market prices, interest rates, indices, volatilities, correlations or other market factors such as liquidity, will result in losses for a certain financial instrument or group of financial instruments.... | 1,008 | 163 | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/0000779152-26-000067-index.htm | https://www.sec.gov/Archives/edgar/data/779152/000077915226000067/jkhy-20260630.htm |
0000056701-26-000034 | 10-K | 2026-08-28 | 2026-06-30 | 56701 | KOSS | KOSS CORP | business | 1 | GENERAL
As used herein unless the context otherwise requires, the term “Company” means Koss Corporation and its subsidiaries, Koss Corp B.V. and Koss U.K. Limited. Koss Corporation was incorporated in Delaware in 1971. It formed Koss Corp B.V. and Koss U.K. Limited to comply with certain European Union (“EU”) requireme... | 16,199 | 2,404 | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/0000056701-26-000034-index.htm | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/koss-20260630x10k.htm |
0000056701-26-000034 | 10-K | 2026-08-28 | 2026-06-30 | 56701 | KOSS | KOSS CORP | risk_factors | 1A | We are subject to various risks that may adversely affect our business, prospects, financial condition, and results of operations, including, but not limited to, those set forth below. These are the risks and uncertainties we believe are most important for you to consider, however, there may be other risks that are cur... | 42,962 | 6,266 | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/0000056701-26-000034-index.htm | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/koss-20260630x10k.htm |
0000056701-26-000034 | 10-K | 2026-08-28 | 2026-06-30 | 56701 | KOSS | KOSS CORP | cybersecurity | 1C | Risk Management and Strategy
The Company maintains policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and has integrated these processes into the overall risk management processes. The Company continued to enhance its cybersecurity program through investments in se... | 3,610 | 481 | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/0000056701-26-000034-index.htm | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/koss-20260630x10k.htm |
0000056701-26-000034 | 10-K | 2026-08-28 | 2026-06-30 | 56701 | KOSS | KOSS CORP | mdna | 7 | The purpose of this discussion and analysis is to enhance the understanding and evaluation of the financial position, results of operations, cash flows, indebtedness, and other key financial information of the Company for fiscal years 2026 and 2025. Unless otherwise indicated, comparisons of financial information refle... | 37,772 | 5,756 | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/0000056701-26-000034-index.htm | https://www.sec.gov/Archives/edgar/data/56701/000005670126000034/koss-20260630x10k.htm |
0001213900-26-094478 | 10-K | 2026-08-28 | 2026-03-31 | 1733861 | null | REST EZ Inc. | business | 1 | The Company was incorporated in the State of Wyoming on October 17, 2016. Rest EZ, Inc. markets a sleeping aid soft gel capsule to be sold to the public through wholesalers and retailers, as well as online at www.RestEz.net. The Rest EZ Sleep Aid Supplement soft gel capsule is a liquid gel capsule containing soybean oi... | 10,153 | 1,593 | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/0001213900-26-094478-index.htm | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/ea0303560-10k_rest.htm |
0001213900-26-094478 | 10-K | 2026-08-28 | 2026-03-31 | 1733861 | null | REST EZ Inc. | risk_factors | 1A | Investing in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this Report. Any of the following risks could harm our business, operating... | 14,765 | 2,345 | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/0001213900-26-094478-index.htm | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/ea0303560-10k_rest.htm |
0001213900-26-094478 | 10-K | 2026-08-28 | 2026-03-31 | 1733861 | null | REST EZ Inc. | cybersecurity | 1C | The Company maintains processes designed to identify, assess, and manage material risks from cybersecurity threats to its information systems. These processes are proportionate to the size and nature of the Company’s operations and are integrated into the Company’s overall risk management practices.
The Company’s cyber... | 1,413 | 186 | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/0001213900-26-094478-index.htm | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/ea0303560-10k_rest.htm |
0001213900-26-094478 | 10-K | 2026-08-28 | 2026-03-31 | 1733861 | null | REST EZ Inc. | mdna | 7 | Forward Looking Statements
The following discussion should be read in conjunction with the consolidated financial statements and the related notes thereto, as well as all other related notes, and financial and operational references, appearing elsewhere in this document.
Certain information contained in this discussion... | 16,289 | 2,522 | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/0001213900-26-094478-index.htm | https://www.sec.gov/Archives/edgar/data/1733861/000121390026094478/ea0303560-10k_rest.htm |
0001193125-26-374333 | 10-K | 2026-08-28 | 2026-06-28 | 933034 | STRT | STRATTEC SECURITY CORP | business | 1 | Overview
Strattec is a global automotive access company that designs and delivers safe, secure, and highly engineered access solutions for the automotive and mobility markets. Built on generations of access and security engineering expertise, we partner closely with OEMs to create differentiated, system level access ex... | 18,946 | 2,724 | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/0001193125-26-374333-index.htm | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/strt-20260628.htm |
0001193125-26-374333 | 10-K | 2026-08-28 | 2026-06-28 | 933034 | STRT | STRATTEC SECURITY CORP | risk_factors | 1A | Investors and readers should carefully consider each of the risks, assumptions, uncertainties and other factors described below and elsewhere in this Annual Report, as well as any amendments or updates reflected in subsequent filings with the Securities and Exchange Commission. We believe these risks, assumptions, unce... | 32,860 | 4,828 | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/0001193125-26-374333-index.htm | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/strt-20260628.htm |
0001193125-26-374333 | 10-K | 2026-08-28 | 2026-06-28 | 933034 | STRT | STRATTEC SECURITY CORP | cybersecurity | 1C | Governance
The Company conducts regular assessments of cybersecurity risks both internally and with third party assistance. Our Chief Information Officer reports on the results of these assessments and corresponding recommendations to the full Board of Directors at least annually. We use the National Institute of Stand... | 2,471 | 339 | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/0001193125-26-374333-index.htm | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/strt-20260628.htm |
0001193125-26-374333 | 10-K | 2026-08-28 | 2026-06-28 | 933034 | STRT | STRATTEC SECURITY CORP | mdna | 7 | The following Management's Discussion and Analysis should be read in conjunction with the accompanying audited consolidated financial statements and notes.
Business Overview
Strattec is a global automotive access company that designs and delivers safe, secure, and highly engineered access solutions for the automotive a... | 25,580 | 3,796 | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/0001193125-26-374333-index.htm | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/strt-20260628.htm |
0001193125-26-374333 | 10-K | 2026-08-28 | 2026-06-28 | 933034 | STRT | STRATTEC SECURITY CORP | market_risk | 7A | We are exposed to market risks in the normal course of business, primarily from changes in interest rates, foreign currency exchange rates, and prices of certain production materials. The disclosures below relate to market risk sensitive instruments and other exposures we believe are material to our business. We do not... | 4,192 | 629 | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/0001193125-26-374333-index.htm | https://www.sec.gov/Archives/edgar/data/933034/000119312526374333/strt-20260628.htm |
0001420720-26-000020 | 10-K | 2026-08-28 | 2026-06-30 | 1420720 | IBIO | iBio, Inc. | business | 1 | Overview
iBio, Inc. (also referred to as “we”, “us”, “our”, “iBio”, or the “Company”) is a clinical-stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. Our core mission is t... | 116,253 | 17,065 | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/0001420720-26-000020-index.htm | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm |
0001420720-26-000020 | 10-K | 2026-08-28 | 2026-06-30 | 1420720 | IBIO | iBio, Inc. | risk_factors | 1A | Summary Risk Factors
Our business faces significant risks and uncertainties of which investors should be aware before making a decision to invest in our Common Stock. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. The f... | 180,706 | 27,568 | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/0001420720-26-000020-index.htm | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm |
0001420720-26-000020 | 10-K | 2026-08-28 | 2026-06-30 | 1420720 | IBIO | iBio, Inc. | cybersecurity | 1C | We maintain a cyber risk management protocol designed to identify, assess, manage, mitigate, and respond to cybersecurity threats.
The underlying processes and controls of our cyber risk management protocol incorporate recognized best practices and standards for cybersecurity and information technology, including the N... | 3,427 | 475 | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/0001420720-26-000020-index.htm | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm |
0001420720-26-000020 | 10-K | 2026-08-28 | 2026-06-30 | 1420720 | IBIO | iBio, Inc. | mdna | 7 | The following discussion of our financial condition and results of operations should be read together with our financial statements and the notes thereto and other information included elsewhere in this Annual Report. Unless the context requires otherwise, references in this Report to “iBio,” the “Company,” “we,” “us,”... | 38,894 | 5,914 | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/0001420720-26-000020-index.htm | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm |
0001420720-26-000020 | 10-K | 2026-08-28 | 2026-06-30 | 1420720 | IBIO | iBio, Inc. | market_risk | 7A | The information under this Item is not required to be provided by smaller reporting companies. | 94 | 15 | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/0001420720-26-000020-index.htm | https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm |
0001683168-26-006788 | 10-K/A | 2026-08-28 | 2025-12-31 | 1756180 | NCRA | NOCERA, INC. | mdna | 7 | The following discussion and analysis of our
financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related
notes included elsewhere in this Annual Report on Form 10-K. Our consolidated financial statements have been prepared in accordance with
U.S... | 38,887 | 5,828 | https://www.sec.gov/Archives/edgar/data/1756180/000168316826006788/0001683168-26-006788-index.htm | https://www.sec.gov/Archives/edgar/data/1756180/000168316826006788/nocera_i10ka2-123125.htm |
0001731122-26-001166 | 10-Q | 2026-08-28 | 2026-03-31 | 1314052 | AVXL | ANAVEX LIFE SCIENCES CORP. | risk_factors | II-1A | Except as otherwise provided herein, there have been
no material changes to the risk factors discussed in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for
the fiscal year ended September 30, 2025, filed with the SEC on November 25, 2025.
The termination of our former CEO’s employment
for Cause, t... | 9,708 | 1,520 | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/0001731122-26-001166-index.htm | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/e7885_10-q.htm |
0001731122-26-001166 | 10-Q | 2026-08-28 | 2026-03-31 | 1314052 | AVXL | ANAVEX LIFE SCIENCES CORP. | mdna | I-2 | OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking
statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements
regarding our anticipated future clinical an... | 44,729 | 7,010 | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/0001731122-26-001166-index.htm | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/e7885_10-q.htm |
0001731122-26-001166 | 10-Q | 2026-08-28 | 2026-03-31 | 1314052 | AVXL | ANAVEX LIFE SCIENCES CORP. | market_risk | I-3 | As a “smaller reporting company”, we are not required to provide
the information required by this item. | 103 | 17 | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/0001731122-26-001166-index.htm | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/e7885_10-q.htm |
0001731122-26-001167 | 10-Q | 2026-08-28 | 2026-06-30 | 1314052 | AVXL | ANAVEX LIFE SCIENCES CORP. | risk_factors | II-1A | Except as otherwise provided herein, there have been
no material changes to the risk factors discussed in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K
for the fiscal year ended September 30, 2025, filed with the SEC on November 25, 2025.
The termination of our former CEO’s employment
for Cause, t... | 9,776 | 1,530 | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/0001731122-26-001167-index.htm | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/e7886_10-q.htm |
0001731122-26-001167 | 10-Q | 2026-08-28 | 2026-06-30 | 1314052 | AVXL | ANAVEX LIFE SCIENCES CORP. | mdna | I-2 | OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking
statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements
regarding our anticipated future clinical an... | 46,719 | 7,281 | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/0001731122-26-001167-index.htm | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/e7886_10-q.htm |
0001731122-26-001167 | 10-Q | 2026-08-28 | 2026-06-30 | 1314052 | AVXL | ANAVEX LIFE SCIENCES CORP. | market_risk | I-3 | As a “smaller reporting company”, we are not required to provide
the information required by this item. | 103 | 17 | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/0001731122-26-001167-index.htm | https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/e7886_10-q.htm |
0000769397-26-000061 | 10-Q | 2026-08-28 | 2026-07-31 | 769397 | ADSK | Autodesk, Inc. | risk_factors | II-1A | We operate in a rapidly changing environment that involves significant risks, a number of which are beyond our control. In addition to the other information contained in this Quarterly Report on Form 10-Q, the following discussion highlights some of these risks and the possible impact of these factors on our business, ... | 104,755 | 15,438 | https://www.sec.gov/Archives/edgar/data/769397/000076939726000061/0000769397-26-000061-index.htm | https://www.sec.gov/Archives/edgar/data/769397/000076939726000061/adsk-20260731.htm |
0000769397-26-000061 | 10-Q | 2026-08-28 | 2026-07-31 | 769397 | ADSK | Autodesk, Inc. | mdna | I-2 | The discussion in our MD&A and elsewhere in this Quarterly Report on Form 10-Q contains trend analyses and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are any statements that look to f... | 57,990 | 9,049 | https://www.sec.gov/Archives/edgar/data/769397/000076939726000061/0000769397-26-000061-index.htm | https://www.sec.gov/Archives/edgar/data/769397/000076939726000061/adsk-20260731.htm |
0000769397-26-000061 | 10-Q | 2026-08-28 | 2026-07-31 | 769397 | ADSK | Autodesk, Inc. | market_risk | I-3 | Foreign Currency Exchange Risk
Our revenue, earnings, cash flows, receivables, and payables are subject to fluctuations due to changes in foreign currency exchange rates. Our risk management strategy utilizes foreign currency contracts to manage our exposure to foreign currency volatility that exists as part of our ong... | 3,569 | 561 | https://www.sec.gov/Archives/edgar/data/769397/000076939726000061/0000769397-26-000061-index.htm | https://www.sec.gov/Archives/edgar/data/769397/000076939726000061/adsk-20260731.htm |
0001493152-26-040661 | 10-Q | 2026-08-28 | 2026-03-31 | 1865861 | CCTSF | Cactus Acquisition Corp. 1 Ltd | mdna | I-2 | Overview
We
are a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share
exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We completed
our initial public offering in Novem... | 14,394 | 2,241 | https://www.sec.gov/Archives/edgar/data/1865861/000149315226040661/0001493152-26-040661-index.htm | https://www.sec.gov/Archives/edgar/data/1865861/000149315226040661/form10-q.htm |
0001493152-26-040661 | 10-Q | 2026-08-28 | 2026-03-31 | 1865861 | CCTSF | Cactus Acquisition Corp. 1 Ltd | market_risk | I-3 | The
net proceeds from our initial public offering and the sale of the private warrants held in the trust account, after reduction for payments
made for the redemption of a portion of the public shares in connection with the first extension meeting, conversion amendment meeting,
second extension meeting, third extension... | 780 | 122 | https://www.sec.gov/Archives/edgar/data/1865861/000149315226040661/0001493152-26-040661-index.htm | https://www.sec.gov/Archives/edgar/data/1865861/000149315226040661/form10-q.htm |
0001707753-26-000054 | 10-Q | 2026-08-28 | 2026-07-31 | 1707753 | ESTC | Elastic N.V. | risk_factors | II-1A | Except as set forth below, there have been no material changes to the risk factors disclosed in “Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K. The risks described in the Company’s Annual Report on Form 10-K and our subsequent SEC reports are not the only risks facing us. There are additional risks... | 2,623 | 400 | https://www.sec.gov/Archives/edgar/data/1707753/000170775326000054/0001707753-26-000054-index.htm | https://www.sec.gov/Archives/edgar/data/1707753/000170775326000054/estc-20260731.htm |
0001707753-26-000054 | 10-Q | 2026-08-28 | 2026-07-31 | 1707753 | ESTC | Elastic N.V. | mdna | I-2 | The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and with our Management’s Discussion and Analysis of Financial Conditio... | 42,390 | 6,612 | https://www.sec.gov/Archives/edgar/data/1707753/000170775326000054/0001707753-26-000054-index.htm | https://www.sec.gov/Archives/edgar/data/1707753/000170775326000054/estc-20260731.htm |
0001707753-26-000054 | 10-Q | 2026-08-28 | 2026-07-31 | 1707753 | ESTC | Elastic N.V. | market_risk | I-3 | We have operations both within the United States and internationally, and we are exposed to interest rate risk and foreign currency risk in the ordinary course of our business.
Interest Rate Risk
We had cash, cash equivalents, restricted cash, and marketable securities totaling $1.463 billion as of July 31, 2026. Our c... | 3,672 | 594 | https://www.sec.gov/Archives/edgar/data/1707753/000170775326000054/0001707753-26-000054-index.htm | https://www.sec.gov/Archives/edgar/data/1707753/000170775326000054/estc-20260731.htm |
0001493152-26-040649 | 10-Q | 2026-08-28 | 2026-06-30 | 1892704 | FBDT | First Breach, Inc. | risk_factors | II-1A | Investing
in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information
in this Quarterly Report on Form 10-Q, before deciding whether to invest in shares of our common stock. If any of the following risks
actually occurs, our business, re... | 117,559 | 18,119 | https://www.sec.gov/Archives/edgar/data/1892704/000149315226040649/0001493152-26-040649-index.htm | https://www.sec.gov/Archives/edgar/data/1892704/000149315226040649/form10-q.htm |
0001493152-26-040649 | 10-Q | 2026-08-28 | 2026-06-30 | 1892704 | FBDT | First Breach, Inc. | mdna | I-2 | You
should read the following discussion and analysis of our financial condition and results of operations in conjunction with our
financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical
information, this discussion and analysis contains forward... | 37,988 | 5,769 | https://www.sec.gov/Archives/edgar/data/1892704/000149315226040649/0001493152-26-040649-index.htm | https://www.sec.gov/Archives/edgar/data/1892704/000149315226040649/form10-q.htm |
0001493152-26-040649 | 10-Q | 2026-08-28 | 2026-06-30 | 1892704 | FBDT | First Breach, Inc. | market_risk | I-3 | We
are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K. | 126 | 21 | https://www.sec.gov/Archives/edgar/data/1892704/000149315226040649/0001493152-26-040649-index.htm | https://www.sec.gov/Archives/edgar/data/1892704/000149315226040649/form10-q.htm |
0001628280-26-059345 | 10-Q | 2026-08-28 | 2026-08-01 | 39911 | GAP | GAP INC | risk_factors | II-1A | There have been no material changes in our risk factors from those disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 31, 2026. | 173 | 33 | https://www.sec.gov/Archives/edgar/data/39911/000162828026059345/0001628280-26-059345-index.htm | https://www.sec.gov/Archives/edgar/data/39911/000162828026059345/gap-20260801.htm |
0001628280-26-059345 | 10-Q | 2026-08-28 | 2026-08-01 | 39911 | GAP | GAP INC | mdna | I-2 | OUR BUSINESS
We are a house of iconic American brands offering apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, and Athleta brands. Our products are available to customers both in stores and online, through Company-operated and franchise stores, web... | 21,396 | 3,504 | https://www.sec.gov/Archives/edgar/data/39911/000162828026059345/0001628280-26-059345-index.htm | https://www.sec.gov/Archives/edgar/data/39911/000162828026059345/gap-20260801.htm |
0001628280-26-059345 | 10-Q | 2026-08-28 | 2026-08-01 | 39911 | GAP | GAP INC | market_risk | I-3 | Our market risk profile as of January 31, 2026 is disclosed in our Annual Report on Form 10-K and has not significantly changed. See Notes 3, 4, and 5 of Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q, for disclosures on our debt and credit facilities, investments, and... | 354 | 59 | https://www.sec.gov/Archives/edgar/data/39911/000162828026059345/0001628280-26-059345-index.htm | https://www.sec.gov/Archives/edgar/data/39911/000162828026059345/gap-20260801.htm |
0001193805-26-001157 | 10-Q | 2026-08-28 | 2026-03-31 | 885462 | GURE | GULF RESOURCES, INC. | risk_factors | II-1A | Investing in our common stock involves a high degree of risk.
Before you invest you should carefully review our Management’s Discussion and Analysis of Financial Condition and Results of Operations
set forth in Item 2 of Part I of this Quarterly Report on Form 10-Q, our consolidated financial statements and related not... | 34,753 | 5,312 | https://www.sec.gov/Archives/edgar/data/885462/000119380526001157/0001193805-26-001157-index.htm | https://www.sec.gov/Archives/edgar/data/885462/000119380526001157/e665726_10q-gulfresources.htm |
0001193805-26-001157 | 10-Q | 2026-08-28 | 2026-03-31 | 885462 | GURE | GULF RESOURCES, INC. | mdna | I-2 | Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
The discussion below contains “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section
21E of the Exchange Act. We have used words such ... | 32,144 | 5,234 | https://www.sec.gov/Archives/edgar/data/885462/000119380526001157/0001193805-26-001157-index.htm | https://www.sec.gov/Archives/edgar/data/885462/000119380526001157/e665726_10q-gulfresources.htm |
0001193805-26-001157 | 10-Q | 2026-08-28 | 2026-03-31 | 885462 | GURE | GULF RESOURCES, INC. | market_risk | I-3 | Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)),
the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined
by Rule 229.10(f)(1). | 207 | 34 | https://www.sec.gov/Archives/edgar/data/885462/000119380526001157/0001193805-26-001157-index.htm | https://www.sec.gov/Archives/edgar/data/885462/000119380526001157/e665726_10q-gulfresources.htm |
0001753926-26-001659 | 10-Q | 2026-08-28 | 2026-07-31 | 357294 | HOV | HOVNANIAN ENTERPRISES INC | mdna | I-2 | Hovnanian Enterprises, Inc. (“HEI”) conducts all of its homebuilding and financial services operations through its consolidated subsidiaries (references herein to the “Company,” “we,” “us” or “our” refer to HEI and its consolidated subsidiaries and should be understood to reflect the consolidated business of HEI’s subs... | 67,286 | 10,999 | https://www.sec.gov/Archives/edgar/data/357294/000175392626001659/0001753926-26-001659-index.htm | https://www.sec.gov/Archives/edgar/data/357294/000175392626001659/hov-20260731.htm |
0001753926-26-001659 | 10-Q | 2026-08-28 | 2026-07-31 | 357294 | HOV | HOVNANIAN ENTERPRISES INC | market_risk | I-3 | Substantially all of our long-term debt requires fixed interest payments and we have limited exposure to variable rates. In connection with our mortgage operations, mortgage loans held for sale and the associated mortgage warehouse lines of credit under our Master Repurchase Agreements are subject to interest rate risk... | 2,116 | 364 | https://www.sec.gov/Archives/edgar/data/357294/000175392626001659/0001753926-26-001659-index.htm | https://www.sec.gov/Archives/edgar/data/357294/000175392626001659/hov-20260731.htm |
0001835632-26-000025 | 10-Q | 2026-08-28 | 2026-08-01 | 1835632 | MRVL | Marvell Technology, Inc. | risk_factors | II-1A | Investing in our common stock involves a high degree of risk. You should carefully consider the material risks and uncertainties described below and all information contained in this report before you decide to purchase our common stock. Many of these risks and uncertainties are beyond our control, including business c... | 158,543 | 24,062 | https://www.sec.gov/Archives/edgar/data/1835632/000183563226000025/0001835632-26-000025-index.htm | https://www.sec.gov/Archives/edgar/data/1835632/000183563226000025/mrvl-20260801.htm |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.